Welcome to our dedicated page for OmniAb news (Ticker: OABI), a resource for investors and traders seeking the latest updates and insights on OmniAb stock.
OmniAb, Inc. (NASDAQ: OABI) news covers developments in its antibody and peptide discovery technologies, partner collaborations, and financial performance. As a licensor of discovery research platforms to pharmaceutical and biotech companies and academic institutions, OmniAb regularly issues updates on how its technologies are being applied in drug discovery programs and on its own corporate activities.
News about OmniAb often highlights advances in its proprietary transgenic animal platforms and related tools. Recent announcements have described the launch of OmniUltra™, a transgenic chicken platform engineered to express ultralong CDRH3 domains on a human antibody framework, which OmniAb characterizes as extending into the peptide space and enabling applications such as bispecifics, multispecifics, CAR-T, radioligands, and peptide therapeutics. The company has also reported on xPloration®, a high-throughput single B-cell screening instrument that leverages machine learning and artificial intelligence for deep antibody mining.
Investors following OABI can expect news items on technology license and services agreements with partners, including arrangements that may provide service revenue, milestones, royalties, and in some cases potential equity. OmniAb’s press releases also summarize partner program milestones, such as clinical trial updates and regulatory progress for OmniAb-derived antibodies, bispecifics, antibody-drug conjugates, and other biologic modalities.
In addition, OmniAb issues periodic financial results and business highlights, including revenue composition across license, milestone, service, xPloration, and royalty streams, as well as information on private placements and guidance ranges. Conference participation, investor events, and scientific presentations at industry meetings are also frequent topics. For readers tracking OmniAb news, this mix of technology, partnership, clinical, and financial updates provides insight into how the company’s platforms are being used across the therapeutic discovery landscape.
OmniAb (NASDAQ: OABI) launched OmniUltra on December 15, 2025, described as the industry’s first transgenic chicken engineered to express ultralong CDRH3 domains on a human antibody framework.
OmniUltra generates human immune repertoires with cow-inspired ultralong CDRH3s and isolates picobodies™ (4–6 kDa), enabling antibodies and peptide therapeutics for bispecifics, CAR-T, radioligands and standalone peptides. The company presented at AET 2025 and will host a Virtual Investor Event today at 5:00 p.m. ET with slides and a replay on its investor site.
OmniAb (NASDAQ: OABI) will host a virtual investor event to unveil OmniUltra on Monday, December 15, 2025 at 5:00 p.m. ET (2:00 p.m. PT). The event is expected to run about one hour and will feature management's overview of OmniUltra, described as a transgenic chicken engineered to express ultralong CDRH3 domains on a human antibody framework.
Topics include the technology platform, market use and applications, and its strategic importance. A live webcast with slides and a replay will be available, and U.S. and international dial-in numbers are provided (Conference ID 44666).
OmniAb (NASDAQ: OABI) entered a technology license and services agreement with Mabtrx Biosciences, a newly formed ArrowMark–Viking joint venture, announced on November 17, 2025. The agreement covers OmniAb-derived antibody discovery programs and obligates OmniAb to provide discovery services to Mabtrx.
Under the deal OmniAb will receive revenue for services performed and is eligible for potential equity and royalties tied to discovery of novel antibodies for targets defined by Mabtrx. Management highlighted the use of OmniAb’s transgenic chicken–based technologies to support the collaboration.
OmniAb (NASDAQ: OABI) reported third quarter 2025 results on November 4, 2025: Q3 revenue $2.2M versus $4.2M year-ago and Q3 net loss $16.5M ($0.14/share). Nine-month revenue was $10.3M and nine-month net loss was $50.6M ($0.46/share).
The company ended September 30, 2025 with $59.5M in cash and equivalents after an August private placement that raised $30M (~$28M net). 2025 guidance: revenue $18–22M, operating expense $82–86M, year-end cash expected $52–56M. OmniAb reported 104 active partners, 399 active programs and 32 programs in clinical development or commercialization; OmniUltra™ launch planned for December 2025.
OmniAb (NASDAQ: OABI) announced management participation in three investor conferences in November 2025. Key events:
- Truist Securities BioPharma Symposium — November 6, Lotte New York Palace Hotel; Matt Foehr, CEO, will hold one-on-one investor meetings.
- Stifel Healthcare Conference — November 11-13, Lotte New York Palace Hotel; Kurt Gustafson, CFO, will hold one-on-one investor meetings on November 12.
- Jefferies Global Healthcare Conference — London — November 17-20, Waldorf Hilton; Matt Foehr will present a corporate overview on November 19 at 8:00 a.m. GMT and hold meetings on November 18-19.
The schedule highlights management access to investors via presentations and one-on-one meetings across U.S. and London industry conferences.
OmniAb (NASDAQ: OABI) will report third quarter 2025 financial results for the three and nine months ended September 30, 2025 after U.S. market close on Tuesday, November 4, 2025. The company will host a conference call and webcast the same day beginning at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss results and business updates.
Participants can join by phone (U.S. dial-in (800) 549 8228; international (646) 564 8277; Conference ID 92631). A live webcast and replay with slides will be available via the company’s webcast link.
OmniAb (NASDAQ: OABI) announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference, scheduled for September 8-10, 2025, at the Lotte New York Palace Hotel. The company's management team will be available for one-on-one meetings with registered investors on September 9, 2025.
Interested investors can schedule meetings through their H.C. Wainwright representative or by emailing meetings@hcwco.com.
OmniAb (NASDAQ: OABI) has announced a private placement to raise approximately $30 million through the sale of 21,254,106 shares of common stock. The shares will be priced at $1.40 per share, with officer and director participants paying $1.85 per share.
The placement, expected to close around August 26, 2025, includes participation from top-tier new and existing investors, along with company officers and directors. Leerink Partners is serving as the sole placement agent. The proceeds will be used for general corporate purposes, and OmniAb will file a registration statement with the SEC for the resale of these shares.
OmniAb (NASDAQ: OABI) reported Q2 2025 financial results, showing revenue of $3.9 million, down from $7.6 million in Q2 2024. The company posted a net loss of $15.9 million ($0.15 per share). Despite lower revenue, OmniAb achieved significant business milestones, reaching 100 active partners and 381 active programs, including 32 OmniAb-derived programs in clinical development or commercialization.
The company launched the xPloration® Partner Access Program and entered six new license agreements. Notable highlights include partner Immunovant initiating Phase 3 trials for IMVT-1402, and Johnson & Johnson's JNJ-5322 showing 100% overall response rate in initial Phase 1 results. OmniAb maintains its 2025 revenue guidance of $20-25 million and expects operating expenses of $85-90 million.
OmniAb (NASDAQ: OABI) has scheduled its second quarter 2025 financial results announcement for August 6, 2025, after U.S. market close. The company will host a conference call and webcast at 4:30 p.m. Eastern time to discuss the results and provide business updates.
Interested parties can access the call via phone using U.S. number (800) 549 8228 or international number (289) 819 1520 with Conference ID 93102. A live webcast with slides will also be available for viewing.